Letter to the Editor Regarding: “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”

Authors

Jorge A. Gomez, GlaxoSmithKline Argentina SA
Javier Nieto Guevara, GlaxoSmithKline plc.
Josefina C. Carlos, University of the East Ramon Magsaysay Memorial Medical Center
Joanne A. de Castro, De La Salle Medical and Health Sciences Institute
Donald Ray Josue, GlaxoSmithKline plc.
Edwin Rodriguez, GlaxoSmithKline plc.

Publication Date

1-1-2022

Document Type

Letter to the Editor

Publication Title

Infectious Diseases and Therapy

First Page

1757

Last Page

1761

APA Citation

Gomez, J., Guevara, J., Carlos, J., de Castro, J., Josue, D., & Rodriguez, E. (2022). Letter to the Editor Regarding: “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”. Infectious Diseases and Therapy, 11, 1757–1761. DOI:10.1007/s40121-022-00640-w